Steven Cohen Crinetics Pharmaceuticals, Inc. Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 2,788,939 shares of CRNX stock, worth $97.7 Million. This represents 0.34% of its overall portfolio holdings.
Number of Shares
2,788,939
Previous 2,300,643
21.22%
Holding current value
$97.7 Million
Previous $118 Million
21.34%
% of portfolio
0.34%
Previous 0.32%
Shares
21 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$318 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$244 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$218 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$215 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$190 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.88B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...